UNSPSC 51182028: Formebolone

This classification denotes an anabolic steroid with the molecular formula C21H28O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z2MMV08KUQ, chemically known as 11alpha,17beta-dihydroxy-17-methyl-3-oxoandrosta-1,4-diene-2-carboxaldehyde but generally known as formebolone, which bears US NIH Compound Identifier 17150. European Medicines Agency schedules Formebolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07783MIG.

UNSPSC 51182028 Formebolone is a Commodity code covering anabolic steroids and related pharmaceutical compounds procured by state and local health systems, correctional facilities, and medical institutions. State and local governments buy formebolone under this code primarily through cooperative purchasing vehicles and multi-source pharmaceutical contracts that bundle generic and branded pharmaceuticals together. The work involves establishing supply agreements with pharmaceutical manufacturers and wholesalers to ensure consistent availability of approved pharmaceutical products across member jurisdictions. Issuing bodies include state departments of health and human services, corrections departments, hospital systems operated by counties and cities, and cooperative purchasing alliances that aggregate demand across multiple states and localities to negotiate volume discounts and standardized pricing structures.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon. The solicitation requires manufacturers to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with products available in the marketplace by May 15, 2026 and resulting agreements effective July 1, 2026. Vendors must meet current Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) compliance, maintain contractual relationships with at least two of the three authorized wholesalers with chargeback systems in place, maintain comprehensive insurance coverage including $5,000,000 commercial general liability per occurrence, and submit pricing through the ePro procurement system in Excel CSV format by the March 26 deadline. The contract term is two years for new responders with optional extensions at MMCAP's discretion, and all products must comply with FDA requirements and possess expiration dates of at least one year from manufacture.